Abstract:The clinical efficacy of tyrosine kinase inhibitors supports the dependence of distinct subsets of cancers on specific driver mutations for survival, a phenomenon called "oncogene addiction." We demonstrate that PUMA and BIM are the key apoptotic effectors of tyrosine kinase inhibitors in breast cancers with amplification of the gene encoding human epidermal growth factor receptor 2 (HER2) and lung cancers with epidermal growth factor receptor (EGFR) mutants. The BH3 domain containing proteins BIM and PUMA can directly activate the proapoptotic proteins BAX and BAK to permeabilize mitochondria, leading to caspase activation and apoptosis. We delineated the signal transduction pathways leading to the induction of BIM and PUMA by tyrosine kinase inhibitors. Inhibition of the mitogen-activated or extracellular signal-regulated protein kinase kinase (MEK)-extracellular signal-regulated kinase (ERK) pathway caused increased abundance of BIM, whereas antagonizing the phosphoinositide 3-kinase (PI3K)-AKT pathway triggered nuclear translocation of the FOXO transcription factors, which directly activated the PUMA promoter. In a mouse breast tumor model, the abundance of PUMA and BIM was increased after inactivation of HER2. Moreover, deficiency of Bim or Puma impaired caspase activation and reduced tumor regression caused by inactivation of HER2. Similarly, deficiency of Puma impeded the regression of EGFR(L858R)-driven mouse lung tumors upon inactivation of the EGFR-activating mutant. Overall, our study identified PUMA and BIM as the sentinels that interconnect kinase signaling networks and the mitochondrion-dependent apoptotic program, which offers therapeutic insights for designing novel cell death mechanism-based anticancer strategies.

PUMA is directly activated by NF- κ B and contributes to TNF- α -induced apoptosis

PUMA, a potent killer with or without p53

PUMA, a Novel Proapoptotic Gene, Is Induced by p53

The Nuclear Function of P53 is Required for Puma-Mediated Apoptosis Induced by Dna Damage

PUMA Induces the Rapid Apoptosis of Colorectal Cancer Cells

PUMA amplifies necroptosis signaling by activating cytosolic DNA sensors

The BH3-only Protein, PUMA, is Involved in Oxaliplatin-Induced Apoptosis in Colon Cancer Cells

Regulation of PUMA- α by p53 in cisplatin-induced renal cell apoptosis

JNK1-dependent PUMA Expression Contributes to Hepatocyte Lipoapoptosis

Puma Overexpression Induces Reactive Oxygen Species Generation And Proteasome-Mediated Stathmin Degradation In Colorectal Cancer Cells

P85 Alpha Acts As A Novel Signal Transducer For Mediation Of Cellular Apoptotic Response To Uv Radiation

Advance in PUMA and Cardiomyocyte Apoptosis

PUMA: a New Target in Cytoprotective and Tumor Therapy

Proliferative and survival effects of PUMA promote angiogenesis

Tumor Protein p63/Nuclear Factor κB Feedback Loop in Regulation of Cell Death

PUMA and BIM Are Required for Oncogene Inactivation–Induced Apoptosis

Mutant p53 drives cancer chemotherapy resistance due to loss of function on activating transcription of PUMA

PUMA expression is significantly reduced in human cutaneous melanomas

Expression of PUMA in Papillary Thyroid Carcinoma and Its Role in Inducing Apoptosis

The role of P53 up-regulated modulator of apoptosis (PUMA) in ovarian development, cardiovascular and neurodegenerative diseases

The Catalytic Subunit of DNA-dependent Protein Kinase Selectively Regulates P53-Dependent Apoptosis but Not Cell-Cycle Arrest.